auto_awesome_motion View all 10 versions
organization

RSU

Riga Stradiņš University
Country: Latvia
21 Projects, page 1 of 5
  • Funder: EC Project Code: 316275
    Partners: RSU
  • Open Access mandate for Publications
    Funder: EC Project Code: 692293
    Overall Budget: 999,475 EURFunder Contribution: 999,475 EUR
    Partners: KI, RSU, IEPOR, UNIWERSYTET LODZKI

    The objective of this Twinning project is to significantly strengthen the research in Riga Stradins University (RSU; Latvia) in the smart specialization area of Latvia “bio-medicine, medical technologies, and biotechnologies” with application to immunotherapy of cancer through building an up-rising connections with two internationally leading research institutions, Institute of Microbiology, Tumor and Cell Biology, Karolinska Institutet (Sweden) and the Department of General Biophysics, University of Lodz (Poland). Both represent centers of excellence in the design, testing and clinical applications of a wide class of immunotherapeuticals, with focus on technologies exploiting naked nucleic acids.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 952376
    Overall Budget: 899,992 EURFunder Contribution: 899,992 EUR
    Partners: Sheba Research Fund, UNIFE, University of Ulm, RSU

    The specific challenge of VirA Twinning project is to enhance networking activities between the Riga Stradins University (RSU) located in Latvia as a Widening country and internationally-leading counterparts at EU level, in the field of autoimmunity research. RSU is an institution that has proven itself over several decades on a local and regional level as an important island of research excellence in viral infection-induced autoimmunity research. Further raising the research excellence requires widening the network and establishing closer cooperation with global leaders in science, sharpening the institutional profile of RSU. Project aims at strengthening the close scientific cooperation with counterparts: in Italy - University of Ferrara, in Germany - Ulm University, and in Israel - Tel-Aviv University. The partner universities are the excellence centres (world leaders) that are forerunners in immunology, virology, morphology and clinical data management and modelling, and are capable of inspiring positive change in the research field and significantly influence future developments at RSU via joint activities. Systemic autoimmune diseases (SAD) are a significant cause of morbidity and mortality worldwide, creating a challenge for researchers and clinicians to find evidence-based solutions for SAD diagnostics, treatment and prevention. Due to the complexity of autoimmune disease research, which requires multidisciplinary approaches, a problem is insufficient research capacity at low-performing EU Member State research institutions. Research capacity, able to deliver precise and early diagnostic is of high importance to move towards the development of methods for personalized medicine and better understanding of triggers and mechanisms in autoimmunity, leading to better understanding of chronic diseases and comorbidities and searching for therapy options. VirA project will optimally address the challenges and strengthen the ERA in autoimmunity.

  • Open Access mandate for Publications
    Funder: EC Project Code: 763721
    Overall Budget: 399,574 EURFunder Contribution: 397,624 EUR
    Partners: RSU STOMATOLOGIJAS INSTITUTS, OSI, RSU, AO-FORSCHUNGSINSTITUT DAVOS, RTU, FAU

    The Rudolfs Cimdins Riga Biomaterials Innovations and Development Centre (RBIDC) is a part of Rigas Tehniska Universitate, Latvia (RTU). The RTU RBIDC research team is composed of chemists, chemical engineers and materials scientists. RTU RBIDC scientists are working on well-defined materials science research areas for bone tissue replacement and regeneration. There has been a long lasting cooperation between RTU RBIDC and the Latvijas Organiskas Sintezes Instituts (LIOS) on investigations of biomaterials developed in RTU RBIDC. LIOS has vast experience in preclinical testing of biological/pharmacological activity in in vitro and in vivo systems. Biomaterials developed at RTU RBIDC, in cooperation with clinicians from the Rigas Stradina Universitate, Latvia (RSU) and Riga Stradins University Institute of Stomatology (RSU IS), which starting from 15 June, 2018 has been added to project as a new partner, have been tested in clinical practice in more than 400 patient cases. RTU RBIDC research fields and scientific capacity will be the core for establishing a new Baltic Biomaterials Centre of Excellence (BBCE) and by adding the crucial experience of RSU, RSU IS and LIOS research fields, full-cycle development of biomaterials will be covered. Establishment of Centre of Excellence will provide an opportunity to combine expertise and infrastructure, to create critical mass and excel at specific field and create spill-over effects between different fields. Within the formation of critical mass in research and development, also the cooperation between industry and research organisations will be encouraged, leading to technology transfer and delivery of new products in the market. Hence BBCE project´s main objective is to establish a joint Baltic Biomaterials Centre of Excellence for advanced biomaterials development based on the long-term strategic cooperation between AO--Forschungsinstitut Davos, Switzerland (ARI) and Friedrich-Alexander-Universitaet Erlangen Nuernberg, Germany (FAU) on the one hand and RTU RBIDC, LIOS, RSU IS and RSU on the other hand.

  • Open Access mandate for Publications
    Funder: EC Project Code: 857287
    Overall Budget: 14,999,900 EURFunder Contribution: 14,999,900 EUR
    Partners: FAU, RSU STOMATOLOGIJAS INSTITUTS, OSI, AO-FORSCHUNGSINSTITUT DAVOS, RTU, RSU

    The Baltic Biomaterials Centre of Excellence (BBCE) overall objective is to develop a joint BBCE for advanced biomaterials development based on the long-term strategic cooperation between Riga Technical University, Latvian Institute of Organic Synthesis , Rīga Stradiņš University and LLC Rīga Stradiņš University Institute of Stomatology, on the one part, and AO Research Institute Davos, Switzerland and Friedrich-Alexander University of Erlangen-Nuremberg, Germany, on the other part. The activities of the BBCE will provide an opportunity to combine existing expertise and infrastructure to create critical mass and excellence in the development of biomaterials for bone regeneration and solutions for creative biomedical applications. The expected impact of the BBCE project through Teaming Phase 2 in long term will be achieved through fruitful cooperation between the BBCE core partners in Latvia and industry (including SMEs) bringing the high performance products into the market, increasing scientific excellence, elevating the impact factor of peer-reviewed publications and Hirsch index in the field of biomaterials. Collecting "critical mass" of high level scientists and/or technology developers will be achieved ensuring career development to provide highly-qualified staff at BBCE core partners able to work in a multinational and interdisciplinary environment and capable to cope with their future career demands in an efficient and innovative way.